Skip to main content
. 2008 Sep 16;105(38):14527–14532. doi: 10.1073/pnas.0805204105

Fig. 5.

Fig. 5.

CD4+CD25+ Tregs are required for tolerance induction by i.v. treatment with ECDI-treated donor splenocytes but not for tolerance maintenance. (A) PC61 treatment at the time of tolerance induction abrogated graft protection in recipients receiving ECDI-treated donor cell infusions. Day 0 indicates the day of islet transplantation. The dotted line indicates the blood glucose level of 250 mg/dl, which was used to diagnose graft rejection. (B) Quantification of the CD4+CD25+Foxp3+ T-cell population in peripheral lymphoid organs from rejecting, tolerized, or PC61-treated recipients on day 15 after transplantation. Data were expressed as the percentage of total CD4+ T cells that were Foxp3+ cells. dLNs = draining lymph nodes; pLNs = peripheral lymph nodes. *Rejecting vs. tolerized, P = 0.0076; **, PC61-treated vs. tolerized, P = 0.0013; #PC61-treated vs. tolerized, P = 0.0086; &PC61-treated vs. tolerized, P = 0.026. (C) Anti-donor IFN-γ production by rejecting, tolerized, or PC61-treated recipients. *Rejecting vs. tolerized, P = 0.0009; **rejecting vs. PC61-treated, P = 0.0012. (D) PC61 treatment in long-term tolerized recipients (n = 3). Treatment was given on day 118 and day 120 after islet transplantation as indicated by the arrows. Blood glucose levels were followed for an additional 50 days after PC61 treatment. (E) Anti-TGF-β treatment at the time of tolerance induction abrogated graft protection in recipients receiving infusions of ECDI-treated donor cell.